Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) is a publicly traded Healthcare sector company. As of May 21, 2026, TAK trades at $16.46 with a market cap of $52.36B and a P/E ratio of 0.00. TAK moved +0.60% today. Year to date, TAK is +6.31%; over the trailing twelve months it is +16.89%. Its 52-week range spans $12.80 to $18.90. Analyst consensus is buy with an average price target of $21.00. Rallies surfaces TAK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Takeda jumps after FY2025 results and new FY2026 outlook update: Takeda reported FY2025 full-year results and issued FY2026 outlook on 2026-05-13. The update highlighted strong pipeline progress and provided new forward guidance, giving investors a same-day fundamental catalyst for the move.
| Metric | Value |
|---|---|
| Price | $16.46 |
| Market Cap | $52.36B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.32% |
| 52-Week High | $18.90 |
| 52-Week Low | $12.80 |
| Volume | 9 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
1 analysts cover TAK: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $21.00.